Blood Tests for Gastric Cancer Screening
Endoscopy with biopsy is the gold standard for gastric cancer screening, not blood tests—blood-based screening should only be considered as an adjunct or when endoscopy is declined. 1
Primary Screening Approach
The most recent and authoritative guidance from the 2025 AGA Clinical Practice Update establishes that endoscopy is the best test for screening individuals at increased risk for gastric cancer 1. Blood tests alone are insufficient for primary screening because:
- They cannot directly visualize premalignant lesions (gastric intestinal metaplasia, dysplasia)
- They lack the ability to obtain tissue for histologic confirmation
- They cannot provide accurate staging of gastric mucosa
Blood Tests as Adjunctive Tools
While not recommended for primary screening, several blood-based biomarkers can serve supportive roles:
Helicobacter pylori Testing
- H. pylori serology (IgG antibodies) should be used for opportunistic screening in high-risk individuals 1
- Eradication is essential for primary prevention
- Consider familial-based testing for household members of H. pylori-positive individuals 1
Serological Gastric Function Markers
The following markers help identify gastric atrophy but require endoscopic confirmation:
- Pepsinogen I (PGI): Decreases with gastric atrophy 2, 3, 4
- Pepsinogen II (PGII): Elevated in gastric ulcer and cancer 2
- PGI/PGII ratio: Low ratios (<3.0-6.15) associated with gastric neoplasms 2, 3
- Gastrin-17 (G-17): Elevated levels (>6.4 pmol/L) correlate with corpus atrophy and gastric neoplasms 2, 3, 4
Combined detection of PGII, PGI/PGII ratio, and G-17 shows AUC of 0.826-0.951 for distinguishing gastric cancer from benign conditions 2, 5, but these findings must trigger endoscopic evaluation, not replace it.
Tumor Markers
These have limited utility for screening but may assist in monitoring known disease:
- CEA (Carcinoembryonic Antigen): Elevated in advanced gastric cancer; ASCO recommends it for monitoring metastatic disease response, not screening 6
- CA19-9: Can be measured every 1-3 months in patients with locally advanced/metastatic disease receiving therapy 6
- CA72-4, CA125, CA242: Show some discriminatory ability when combined with gastric function markers (AUC 0.938) 5, but insufficient as standalone screening tools
Emerging Biomarkers
- Soluble HLA-G (sHLA-G): Recent 2025 data shows promise with AUC 0.89 when combined with PGR and G-17 7, but requires validation before clinical implementation
- Trefoil Factor 3 (TFF3): Shows potential in three-dimensional biomarker panels 5
Clinical Algorithm for High-Risk Populations
For individuals at increased risk (first-generation immigrants from high-incidence regions, first-degree relatives with gastric cancer, hereditary syndromes) 1:
Primary approach: High-quality upper endoscopy with systematic biopsy protocol (minimum 5 biopsies from antrum/incisura and corpus) 1
Adjunctive blood testing:
- H. pylori serology for opportunistic screening
- Consider PGI, PGII, PGI/PGII ratio, and G-17 to identify individuals who may benefit from endoscopy
- If serological markers suggest atrophy (low PGI/PGII ratio, elevated G-17), proceed directly to endoscopy
Not recommended: Routine tumor markers (CEA, CA19-9, CA72-4) for screening asymptomatic individuals
Critical Caveats
- No blood test replaces endoscopy for definitive diagnosis 1
- Single-panel testing has very low sensitivity; combined biomarker panels perform better but still require endoscopic confirmation 2, 5
- Serological markers are influenced by H. pylori status, proton pump inhibitor use, and renal function 3
- Population-based blood screening is not cost-effective in low-incidence populations like the United States 8, 9
- The optimal screening intervals for blood-based markers are not well-defined 1
Bottom line: Blood tests may help risk-stratify patients and identify those who need endoscopy, but they cannot substitute for direct visualization and histologic confirmation in gastric cancer screening.